Coherus to launch adalimumab biosimilar in US at 85% discount

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.In a company press release, Coherus announced that it plans to launch Yusimry (adalimumab-aqvh) in July 2023 at a list price of $995 per carton — each containing two 40 mg/0.8 mL autoinjectors — representing a substantial discount relative to the current $6,922 price tag for a carton of Humira (adalimumab, AbbVie).“Our Yusimry list price is a clear response to the challengesRead More